PerpEquities

Eli Lilly and Company (LLY) balance sheet

NYSE · Healthcare · Drug Manufacturers - General · 50,000 employees · CEO David A. Ricks

Price
$1,417.54 +3.19%
Market cap
$1.33T
Enterprise value
$1.38T
Last report
Q3 '26 filed 2026-10-29
Next report
2027-02-03 EPS est. $11.07

At the end of Q3 '26 Eli Lilly and Company (LLY) held $4.89B in cash and short-term investments against $49.5B of debt incl. leases. Total assets $148B, total liabilities $108B, shareholders' equity $40.3B.

Balance sheet

Balance sheetTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Assets
Cash & equivalents$2.82B$2.46B$3.22B$3.37B$3.27B$3.09B$3.38B$9.79B$7.16B$5.14B$8.89B$4.89B
Short-term investments$109M$126M$140M$149M$155M$127M$170M$122M$105M$146M$60M$0
Receivables$11.3B$10B$13.1B$12.1B$13.3B$14B$17.2B$19.5B$20.2B$21.2B$23.5B$25.2B
Inventory$5.77B$6.1B$6.48B$7.46B$7.59B$9.31B$11B$12.2B$13.7B$14.5B$16.8B$18.2B
Other current assets$150M$139M$142M$135M$111M$72.4M$68.8M$272M$147M$214M$86M$91M
Current assets$25.7B$25.2B$30.2B$31.4B$32.7B$41.3B$49.9B$62.1B$55.6B$54.8B$64.7B$65.3B
Property, plant & equipment (net)$12.9B$13.6B$14.8B$16.2B$17.1B$18.5B$20.5B$22.3B$24.7B$26.5B$29.3B$32.2B
Long-term investments$3.05B$3.09B$2.92B$3.2B$3.22B$3.22B$3.21B$2.81B$2.8B$3.12B$3.86B$4.01B
Goodwill$4.94B$4.94B$5.77B$5.77B$5.77B$5.77B$5.77B$5.9B$5.9B$6.13B$8.85B$9.87B
Intangible assets$6.91B$6.76B$6.64B$6.54B$6.17B$6.01B$5.91B$6.45B$6.52B$7.37B$18.1B$18.1B
Deferred tax assets$5.48B$5.63B$6.66B$7.39B$8B$8.57B$9.43B$8.96B$9.96B$11.4B$10B$11B
Other non-current assets$4.99B$4.71B$4.86B$5.12B$5.72B$6.07B$6.23B$6.43B$6.99B$7.23B$7.48B$7.7B
Non-current assets$38.3B$38.8B$41.7B$44.2B$46B$48.1B$51.1B$52.9B$56.8B$61.7B$77.6B$82.8B
Total assets$64B$63.9B$71.9B$75.6B$78.7B$89.4B$101B$115B$112B$117B$142B$148B
Liabilities
Accounts payable$2.6B$2.47B$2.92B$2.89B$3.23B$3.44B$4.08B$4.26B$5.38B$5.03B$6.11B$5.79B
Accrued expenses$11.7B$844M$12.4B$1.7B$11.5B$11.6B$14.5B$17.6B$17.4B$17.5B$22.9B$26.5B
Short-term debt$6.9B$1.65B$5.16B$2.07B$5.12B$4.02B$5.72B$1.63B$1.64B$4B$7.05B$2.52B
Taxes payable$3.85B$4.19B$3.5B$3.88B$0$6.18B$6.96B$9.44B$0$5.29B$5.46B$0
Other current liabilities$4.93B$13.6B$5.42B$18B$7.15B$4.88B$6.38B$7.18B$10.8B$10.1B$11.7B$12.2B
Current liabilities$27.3B$18.6B$27.1B$24.7B$28.4B$30.1B$39B$40.1B$35.2B$36.6B$47.7B$47B
Long-term debt$18.3B$24.6B$23.7B$29B$28.5B$34.5B$34.2B$40.9B$40.9B$39.4B$47.9B$47B
Deferred tax liabilities$0$0$0$0$0$0$0$0$0$0$5.46B$0
Other non-current liabilities$7.53B$7.89B$7.39B$7.57B$7.54B$8.97B$9.37B$10.1B$9.85B$9.37B$7.34B$13.8B
Non-current liabilities$25.8B$32.4B$31.1B$36.6B$36.1B$43.5B$43.6B$50.9B$50.7B$48.7B$60.7B$60.8B
Total liabilities$53.1B$51B$58.2B$61.3B$64.4B$73.5B$82.6B$91.1B$85.9B$85.4B$108B$108B
Equity
Common stock & paid-in capital$594M$594M$594M$594M$592M$593M$592M$591M$590M$590M$588M$588M
Retained earnings$10.3B$12.6B$13.2B$13.6B$13.5B$15.1B$17.4B$22.3B$24.5B$29.5B$31.9B$38B
Accumulated other comprehensive income-$4.33B-$4.3B-$4.38B-$4.27B-$4.32B-$3.77B-$3.72B-$3.21B-$2.88B-$2.83B-$2.76B-$2.63B
Shareholders' equity$10.8B$12.8B$13.6B$14.2B$14.2B$15.8B$18.3B$23.8B$26.5B$31.2B$33.9B$40.3B
Debt
Total debt (incl. leases)$25.2B$26.2B$28.9B$31.1B$33.6B$38.5B$39.9B$42.5B$42.5B$43.4B$54.9B$49.5B
Net debt (debt - cash)$22.4B$23.8B$25.7B$27.8B$30.4B$35.4B$36.5B$32.7B$35.3B$38.2B$46B$44.6B

Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Cash, investments and debt

quarter ends

The other statements

Sources

Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-01